GeneDx Announces Whole Genome Sequencing (WGS) Product Enhancements to Accelerate Diagnoses for More Patients

Go back to GeneDx Announces Whole Genome Sequencing (WGS) Product Enhancements to Accelerate Diagnoses for More Patients

GeneDx (WGS) PT Raised to $45 at BTIG

July 31, 2024 4:57 AM EDT

BTIG analyst Mark Massaro raised the price target on GeneDx (NASDAQ: WGS) to $45.00 (from $35.00) while maintaining a Buy rating.

The analyst comments "Shares of WGS are indicating up +10% AH following another strong quarterly beat-and-raise. WGS drove a ~$10M revenue beat (~16%... More